Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 20

^{Published on 2012-07-31 13:46:09 - Market Wire}
 

Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for... -- SAN DIEGO, July 31, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about OREX

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [ OREX ]), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the second quarter ended June 30, 2012 on Tuesday, August 7, 2012 before the markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 771-4371 (domestic) or (847) 585-4405 (international), participant code 33012560. The webcast can be accessed live on the investor relations section of the Orexigen web site at [ www.orexigen.com ] and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at [ www.orexigen.com ].

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600

SOURCE Orexigen Therapeutics, Inc.

RELATED LINKS
[ http://www.orexigen.com ]